To clarify the role of short-term Androgen deprivation therapy (ADT) in the context of
intermediate unfavorable and a subclass of high-risk patients treated with prostate
Stereotactic radiotherapy (SRT).
In intermediate unfavorable risk group, when choosing standard external beam radiotherapy,
short term ADT is superior in terms of biochemical disease free survival (bDFS) to EBRT
alone. In high risk disease, results of the combination therapy are even more clear. Prostate
SRT has been endorsed as option for primary radical treatment for prostate cancer. In such
patients, the benefit of ADT is still unknown and the decision is left to clinical judgement.
For these reasons, it seems to be relevant to propose a randomized, open label, phase III
clinical trial of prostate SBRT + 6 months ADT versus prostate SBRT alone in intermediate
unfavorable and a subgroup of high risk prostate cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Marco Lorenzo Bonu
Collaborator:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia